Local recommendations (Cardiovascular)
Diuretics
| Recommendation | Approval date | Review date |
| Hydrochlorothiazide EKPG EKHUFT | February 2019 | February 2022 |
| Metolazone (Xaqua®) Position Statement | June 2024 | June 2026 |
| Metolazone (Xaqua®) Information for Patients | June 2024 | June 2026 |
Hypertension and Heart Failure
| Recommendation | Approval date | Review date |
| EKPG Recommendation - Sacubitril Valsartan | November 2016 | November 2019 |
| Sacubitril Valsartan GP letter | June 2016 | April 2021 |
| Sacubitril valsartan GP summary | June 2016 | April 2021 |
| Midodrine prescribing information sheet (V2) | April 2016 | April 2021 |
| B195. Doxazosin MR 2.0 | January 2018 | January 2021 |
| K&M Implementation of NICE TA’s – SGLT2 inhibitors (Dapagliflozin & Empagliflozin) in the treatment of chronic heart failure | December 2023 | December 2025 |
Nitrates, calcium-channel blockers, and other antianginal drugs
| Recommendation | Approval date | Review date |
| Chronic Heart Failure -ECK Ivabradine NICE TA 267 | July 2015 | April 2021 |
Lipid modifying drugs
| Recommendation | Approval date | Review date |
| Alirocumab & Evoculumab, GP update on Implementation of NICE TAs 393 & 394 | November 2017 | November 2020 |
| EKPG Recommendation - Evolocumab and alirocumab for hypercholesterolaemia | April 2017 | April 2020 |
| Implementation Guidance for NICE TA 694 - Bempedoic Acid | September 2021 | September 2022 |
| Summary of national guidance for lipid management for primary and secondary prevention of CVD | ||
| Kent & Medway ICB Position Statement for Prescribing Inclisiran | July 2023 | July 2025 |
Antithrombotic drugs
General (Cardio)
| Recommendation | Approval date | Review date |
| Rituximab for the treatment of immune thrombocytopenic purpura, EKPG Recommendation | December 2015 | April 2021 |
| Dapagliflozin in CKD guide | June 2022 | June 2024 |